Kymera Therapeutics, Inc. (KYMR) — Stock Valuation & Research

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis.…

KYMR key statistics

Price$129.18
Market cap$11.03B
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range55.66-133.875
Beta1.98

Explore KYMR's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.